These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 26742963)
1. Adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: updated results of the Seoul National University Hospital experience. Kim HS; Lee JS; Jeong CW; Kwak C; Kim HH; Ku JH Int Braz J Urol; 2015; 41(6):1067-79. PubMed ID: 26742963 [TBL] [Abstract][Full Text] [Related]
7. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. Xylinas E; Rink M; Margulis V; Clozel T; Lee RK; Comploj E; Novara G; Raman JD; Lotan Y; Weizer A; Roupret M; Pycha A; Scherr DS; Seitz C; Ficarra V; Trinh QD; Karakiewicz PI; Montorsi F; Zerbib M; Shariat SF; BJU Int; 2013 Aug; 112(4):453-61. PubMed ID: 23464979 [TBL] [Abstract][Full Text] [Related]
8. Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study. Kang HW; Seo SP; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YD; Ha YS; Kim TH; Kwon TG; Byun SS; Jeh SU; Kim WJ J Korean Med Sci; 2017 Feb; 32(2):335-342. PubMed ID: 28049247 [TBL] [Abstract][Full Text] [Related]
9. Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. Fairey AS; Kassouf W; Estey E; Tanguay S; Rendon R; Bell D; Izawa J; Chin J; Kapoor A; Matsumoto E; Black P; So A; Lattouf JB; Saad F; Drachenberg D; Cagiannos I; Lacombe L; Fradet Y; Jacobsen NE BJU Int; 2013 Oct; 112(6):791-7. PubMed ID: 23148712 [TBL] [Abstract][Full Text] [Related]
10. Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy. Lee KS; Kim KH; Yoon YE; Choi KH; Yang SC; Han WK Korean J Urol; 2015 Jan; 56(1):41-7. PubMed ID: 25598935 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Real-World, Retrospective Study. Lee J; Lim SH; Chung JH; Song W; Sung HH; Jeong BC; Park SH Cancer Res Treat; 2024 Jul; 56(3):871-876. PubMed ID: 38228080 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. Czito B; Zietman A; Kaufman D; Skowronski U; Shipley W J Urol; 2004 Oct; 172(4 Pt 1):1271-5. PubMed ID: 15371822 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. Hellenthal NJ; Shariat SF; Margulis V; Karakiewicz PI; Roscigno M; Bolenz C; Remzi M; Weizer A; Zigeuner R; Bensalah K; Ng CK; Raman JD; Kikuchi E; Montorsi F; Oya M; Wood CG; Fernandez M; Evans CP; Koppie TM J Urol; 2009 Sep; 182(3):900-6. PubMed ID: 19616245 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Soga N; Arima K; Sugimura Y Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862 [TBL] [Abstract][Full Text] [Related]
16. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. Rink M; Robinson BD; Green DA; Cha EK; Hansen J; Comploj E; Margulis V; Raman JD; Ng CK; Remzi M; Bensalah K; Kabbani W; Haitel A; Rioux-Leclercq N; Guo CC; Chun FK; Kikuchi E; Kassouf W; Sircar K; Sun M; Sonpavde G; Lotan Y; Pycha A; Karakiewicz PI; Scherr DS; Shariat SF J Urol; 2012 Aug; 188(2):398-404. PubMed ID: 22698626 [TBL] [Abstract][Full Text] [Related]
17. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. Aziz A; Dobruch J; Hendricksen K; Kluth LA; Necchi A; Noon A; Rink M; Roghmann F; Seiler R; Gontero P; Kassouf W; Shariat SF; Xylinas E; World J Urol; 2017 Sep; 35(9):1401-1407. PubMed ID: 28074261 [TBL] [Abstract][Full Text] [Related]
18. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract. Cho KS; Joung JY; Seo HK; Cho IC; Chung HS; Chung J; Lee KH Cancer Chemother Pharmacol; 2011 Apr; 67(4):769-74. PubMed ID: 20532510 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity. Luo Y; Feng B; Wei D; Han Y; Li M; Zhao J; Lin Y; Hou Z; Jiang Y Sci Rep; 2020 Oct; 10(1):17674. PubMed ID: 33077839 [TBL] [Abstract][Full Text] [Related]
20. The effect of contralateral kidney volume on renal function after radical nephroureterectomy: Implications for eligibility for neoadjuvant chemotherapy for upper tract urothelial cancer. Song W; Sung HH; Han DH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG Urol Oncol; 2017 Mar; 35(3):114.e1-114.e7. PubMed ID: 27908680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]